Published in J Biol Chem on June 16, 2010
The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res (2012) 3.00
Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci (2011) 2.84
Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol (2011) 2.70
The seeds of neurodegeneration: prion-like spreading in ALS. Cell (2011) 2.03
ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci U S A (2013) 1.48
Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43). J Biol Chem (2012) 1.43
RNA-binding proteins with prion-like domains in ALS and FTLD-U. Prion (2011) 1.40
TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol Med (2011) 1.38
Exome sequencing reveals DNAJB6 mutations in dominantly-inherited myopathy. Ann Neurol (2012) 1.35
TDP-43 aggregation in neurodegeneration: are stress granules the key? Brain Res (2012) 1.35
Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol (2013) 1.32
Implications of the prion-related Q/N domains in TDP-43 and FUS. Prion (2011) 1.25
Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. Hum Mol Genet (2013) 1.21
TDP-43-based animal models of neurodegeneration: new insights into ALS pathology and pathophysiology. Neurodegener Dis (2010) 1.19
TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets. Neurotherapeutics (2015) 1.15
TDP-43: the relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. FEBS J (2011) 1.09
Cellular model of TAR DNA-binding protein 43 (TDP-43) aggregation based on its C-terminal Gln/Asn-rich region. J Biol Chem (2012) 1.08
The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity and inclusion formation. Hum Mol Genet (2013) 1.02
Hyperphosphorylation as a defense mechanism to reduce TDP-43 aggregation. PLoS One (2011) 1.00
Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. Acta Neuropathol (2012) 0.99
The self-interaction of native TDP-43 C terminus inhibits its degradation and contributes to early proteinopathies. Nat Commun (2012) 0.99
Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones. Hum Mol Genet (2013) 0.99
The structural integrity of TDP-43 N-terminus is required for efficient aggregate entrapment and consequent loss of protein function. Prion (2015) 0.97
TDP-43 loss of cellular function through aggregation requires additional structural determinants beyond its C-terminal Q/N prion-like domain. Hum Mol Genet (2014) 0.94
PolyQ disease: misfiring of a developmental cell death program? Trends Cell Biol (2012) 0.93
Structural transformation of the amyloidogenic core region of TDP-43 protein initiates its aggregation and cytoplasmic inclusion. J Biol Chem (2013) 0.92
Selective forelimb impairment in rats expressing a pathological TDP-43 25 kDa C-terminal fragment to mimic amyotrophic lateral sclerosis. Mol Ther (2013) 0.92
RNA-binding proteins in neurodegenerative disease: TDP-43 and beyond. Wiley Interdiscip Rev RNA (2011) 0.90
Myopathy-causing mutations in an HSP40 chaperone disrupt processing of specific client conformers. J Biol Chem (2014) 0.90
Stress and aging induce distinct polyQ protein aggregation states. Proc Natl Acad Sci U S A (2012) 0.88
UBE2E ubiquitin-conjugating enzymes and ubiquitin isopeptidase Y regulate TDP-43 protein ubiquitination. J Biol Chem (2014) 0.88
ALS-Causing Mutations Significantly Perturb the Self-Assembly and Interaction with Nucleic Acid of the Intrinsically Disordered Prion-Like Domain of TDP-43. PLoS Biol (2016) 0.87
TDP-43 N terminus encodes a novel ubiquitin-like fold and its unfolded form in equilibrium that can be shifted by binding to ssDNA. Proc Natl Acad Sci U S A (2014) 0.86
An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors. Hum Mol Genet (2011) 0.84
Inhibition of TDP-43 aggregation by nucleic acid binding. PLoS One (2013) 0.83
Two mutations G335D and Q343R within the amyloidogenic core region of TDP-43 influence its aggregation and inclusion formation. Sci Rep (2016) 0.83
The function of RNA-binding proteins at the synapse: implications for neurodegeneration. Cell Mol Life Sci (2015) 0.83
Heterologous aggregates promote de novo prion appearance via more than one mechanism. PLoS Genet (2015) 0.82
Evolutionarily conserved heterogeneous nuclear ribonucleoprotein (hnRNP) A/B proteins functionally interact with human and Drosophila TAR DNA-binding protein 43 (TDP-43). J Biol Chem (2014) 0.82
RNA-Binding Proteins in Amyotrophic Lateral Sclerosis and Neurodegeneration. Neurol Res Int (2012) 0.81
Protein misfolding specifies recruitment to cytoplasmic inclusion bodies. J Cell Biol (2016) 0.81
Proteins with Intrinsically Disordered Domains Are Preferentially Recruited to Polyglutamine Aggregates. PLoS One (2015) 0.80
Casein kinase II induced polymerization of soluble TDP-43 into filaments is inhibited by heat shock proteins. PLoS One (2014) 0.80
RNP2 of RNA recognition motif 1 plays a central role in the aberrant modification of TDP-43. PLoS One (2013) 0.79
An Amyloid-Like Pathological Conformation of TDP-43 Is Stabilized by Hypercooperative Hydrogen Bonds. Front Mol Neurosci (2016) 0.78
Tunicamycin produces TDP-43 cytoplasmic inclusions in cultured brain organotypic slices. J Neurol Sci (2012) 0.78
Identification of genetic modifiers of TDP-43 neurotoxicity in Drosophila. PLoS One (2013) 0.78
Lentiviral vector-mediated overexpression of mutant ataxin-7 recapitulates SCA7 pathology and promotes accumulation of the FUS/TLS and MBNL1 RNA-binding proteins. Mol Neurodegener (2016) 0.77
Histone methylation restrains the expression of subtype-specific genes during terminal neuronal differentiation in Caenorhabditis elegans. PLoS Genet (2013) 0.77
In vitro prion-like behaviour of TDP-43 in ALS. Neurobiol Dis (2016) 0.76
DNAJB6 Myopathies: Focused Review on an Emerging and Expanding Group of Myopathies. Front Mol Biosci (2016) 0.75
Genome-Wide Identification and Characterization of bZIP Transcription Factors in Brassica oleracea under Cold Stress. Biomed Res Int (2016) 0.75
A novel Drosophila model of TDP-43 proteinopathies: N-terminal sequences combined with the Q/N domain induce protein functional loss and locomotion defects. Dis Model Mech (2016) 0.75
Heat Shock-induced Phosphorylation of TAR DNA-binding Protein 43 (TDP-43) by MAPK/ERK Kinase Regulates TDP-43 Function. J Biol Chem (2017) 0.75
RNA-binding proteins in neurodegeneration: mechanisms in aggregate. Genes Dev (2017) 0.75
Autophagy and Its Impact on Neurodegenerative Diseases: New Roles for TDP-43 and C9orf72. Front Mol Neurosci (2017) 0.75
Point mutations in transactive response DNA-binding protein 43 (TDP-43)'s N-terminal domain compromise its stability, dimerization and functions. J Biol Chem (2017) 0.75
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science (2008) 14.09
Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science (2009) 13.45
Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science (2009) 12.99
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature (2004) 11.82
TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet (2008) 9.51
Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell (1997) 7.59
Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A (1994) 6.96
Stress granule assembly is mediated by prion-like aggregation of TIA-1. Mol Biol Cell (2004) 6.04
TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol (2008) 5.58
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J (2001) 5.23
Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol (1995) 5.18
Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem (2001) 4.87
Rethinking ALS: the FUS about TDP-43. Cell (2009) 4.71
Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet (2005) 4.66
A census of glutamine/asparagine-rich regions: implications for their conserved function and the prediction of novel prions. Proc Natl Acad Sci U S A (2000) 4.19
TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A (2009) 4.18
Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science (2001) 4.13
TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem (2005) 3.99
Global changes to the ubiquitin system in Huntington's disease. Nature (2007) 3.91
Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2009) 3.65
Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem (2008) 3.56
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics (2004) 3.51
Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol (2009) 3.50
Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell (2001) 3.41
TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A (2010) 3.39
Human, Drosophila, and C.elegans TDP43: nucleic acid binding properties and splicing regulatory function. J Mol Biol (2005) 3.33
Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc Natl Acad Sci U S A (1999) 3.33
TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem (2009) 3.29
TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann Neurol (2008) 2.92
Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum Mol Genet (2003) 2.89
Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron (2002) 2.67
A huntingtin-associated protein enriched in brain with implications for pathology. Nature (1995) 2.67
Aplysia CPEB can form prion-like multimers in sensory neurons that contribute to long-term facilitation. Cell (2010) 2.65
Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci (2008) 2.63
Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. J Biol Chem (2009) 2.60
TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. Proc Natl Acad Sci U S A (2008) 2.58
Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum Mol Genet (2009) 2.50
Depletion of TDP-43 affects Drosophila motoneurons terminal synapsis and locomotive behavior. FEBS Lett (2009) 2.48
TDP-43 is a developmentally regulated protein essential for early embryonic development. J Biol Chem (2009) 2.40
TDP-43, a neuro-pathosignature factor, is essential for early mouse embryogenesis. Genesis (2010) 2.31
Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum Mol Genet (2009) 2.23
Polyglutamine protein aggregates are dynamic. Nat Cell Biol (2002) 2.21
Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell (2004) 2.19
Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet (2001) 2.16
A motor neuron disease-associated mutation in p150Glued perturbs dynactin function and induces protein aggregation. J Cell Biol (2006) 2.08
TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry (2008) 2.07
Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology (2008) 2.01
Splicing factors induce cystic fibrosis transmembrane regulator exon 9 skipping through a nonevolutionary conserved intronic element. J Biol Chem (2000) 2.00
Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet (2007) 1.95
Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum Mol Genet (1999) 1.95
The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. Proc Natl Acad Sci U S A (2005) 1.89
A novel CpG-free vertebrate insulator silences the testis-specific SP-10 gene in somatic tissues: role for TDP-43 in insulator function. J Biol Chem (2007) 1.83
Impaired protein aggregate handling and clearance underlie the pathogenesis of p97/VCP-associated disease. J Biol Chem (2008) 1.82
Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo. Nucleic Acids Res (2009) 1.77
Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy: implications for TDP-43 in the physiological response to neuronal injury. Brain Res (2008) 1.77
Nuclear functions of heterogeneous nuclear ribonucleoproteins A/B. Cell Mol Life Sci (2009) 1.75
Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat Cell Mol Genet (1998) 1.72
Regulation of heterogenous nuclear ribonucleoprotein A1 transport by phosphorylation in cells stressed by osmotic shock. Proc Natl Acad Sci U S A (2005) 1.65
A method to assess compositional bias in biological sequences and its application to prion-like glutamine/asparagine-rich domains in eukaryotic proteomes. Genome Biol (2003) 1.61
Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol (2008) 1.56
The molecular links between TDP-43 dysfunction and neurodegeneration. Adv Genet (2009) 1.46
RNA-binding protein TLS is a major nuclear aggregate-interacting protein in huntingtin exon 1 with expanded polyglutamine-expressing cells. J Biol Chem (2007) 1.46
A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron (2003) 1.45
TDP-43 depletion induces neuronal cell damage through dysregulation of Rho family GTPases. J Biol Chem (2009) 1.44
Abnormal TDP-43 expression is identified in the neocortex in cases of dementia pugilistica, but is mainly confined to the limbic system when identified in high and moderate stages of Alzheimer's disease. Neuropathology (2010) 1.37
Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol Cell Biol (2008) 1.35
Prions: proteins as genes and infectious entities. Genes Dev (2004) 1.29
Cross-seeding fibrillation of Q/N-rich proteins offers new pathomechanism of polyglutamine diseases. J Neurosci (2009) 1.16
Purification of polyglutamine aggregates and identification of elongation factor-1alpha and heat shock protein 84 as aggregate-interacting proteins. J Neurosci (2002) 1.15
Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor. EMBO J (2008) 1.14
Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington's disease. J Biol Chem (2003) 1.13
Regulation of synaptic Pumilio function by an aggregation-prone domain. J Neurosci (2010) 1.02
SAFB1's multiple functions in biological control-lots still to be done! J Cell Biochem (2010) 0.93
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem (2009) 5.76
TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol (2008) 5.58
TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A (2009) 4.18
Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature (2013) 4.03
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci (2009) 3.68
Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol (2009) 3.50
Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A (2013) 2.95
Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med (2013) 2.89
Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. J Neurosci (2010) 2.55
Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem (2012) 2.42
Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J Biol Chem (2008) 2.34
Anemia, paresthesias, and gait ataxia in a 57-year-old denture wearer. Clin Chem (2011) 2.02
In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci (2011) 2.00
Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet (2007) 1.95
The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. Proc Natl Acad Sci U S A (2005) 1.89
Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A (2013) 1.88
Impaired protein aggregate handling and clearance underlie the pathogenesis of p97/VCP-associated disease. J Biol Chem (2008) 1.82
Inclusion body myopathy, Paget's disease of the bone and fronto-temporal dementia: a disorder of autophagy. Hum Mol Genet (2010) 1.75
Endolysosomal sorting of ubiquitylated caveolin-1 is regulated by VCP and UBXD1 and impaired by VCP disease mutations. Nat Cell Biol (2011) 1.69
Transgenic mice expressing the Nmnat1 protein manifest robust delay in axonal degeneration in vivo. J Neurosci (2009) 1.69
Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve (2009) 1.57
Quantitation of "autophagic flux" in mature skeletal muscle. Autophagy (2010) 1.53
Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol (2013) 1.51
A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron (2003) 1.45
Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy. J Biol Chem (2006) 1.41
Non-competitive androgen receptor inhibition in vitro and in vivo. Proc Natl Acad Sci U S A (2009) 1.37
Exome sequencing reveals DNAJB6 mutations in dominantly-inherited myopathy. Ann Neurol (2012) 1.35
Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol Cell Biol (2008) 1.35
Myosin binding protein C1: a novel gene for autosomal dominant distal arthrogryposis type 1. Hum Mol Genet (2010) 1.32
Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through polarity protein Par-3/atypical protein kinase C (aPKC) signaling. Proc Natl Acad Sci U S A (2011) 1.29
Inflammatory myopathies with mitochondrial pathology and protein aggregates. J Neurol Sci (2008) 1.28
Implications of the prion-related Q/N domains in TDP-43 and FUS. Prion (2011) 1.25
Quantitation of selective autophagic protein aggregate degradation in vitro and in vivo using luciferase reporters. Autophagy (2009) 1.25
Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotemporal Degener (2013) 1.21
TDP-43-based animal models of neurodegeneration: new insights into ALS pathology and pathophysiology. Neurodegener Dis (2010) 1.19
Mitofusin2 mutations disrupt axonal mitochondrial positioning and promote axon degeneration. J Neurosci (2012) 1.18
Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice. Neurobiol Dis (2009) 1.16
p97/VCP at the intersection of the autophagy and the ubiquitin proteasome system. Autophagy (2010) 1.16
Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes. Ann Neurol (2014) 1.15
Schwann cell mitochondrial metabolism supports long-term axonal survival and peripheral nerve function. J Neurosci (2011) 1.15
Biologically active molecules that reduce polyglutamine aggregation and toxicity. Hum Mol Genet (2006) 1.14
Misexpression of Pou3f1 results in peripheral nerve hypomyelination and axonal loss. J Neurosci (2007) 1.13
Motor neuron involvement in multisystem proteinopathy: implications for ALS. Neurology (2013) 1.08
Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis. Neurobiol Aging (2013) 1.08
GFRalpha1 expression in cells lacking RET is dispensable for organogenesis and nerve regeneration. Neuron (2004) 1.04
Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract. Endocrinology (2006) 1.04
A cellular conformation-based screen for androgen receptor inhibitors. ACS Chem Biol (2008) 1.03
Structure of artemin complexed with its receptor GFRalpha3: convergent recognition of glial cell line-derived neurotrophic factors. Structure (2006) 1.02
Cellular mechanisms of protein aggregate propagation. Curr Opin Neurol (2012) 1.01
Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones. Hum Mol Genet (2013) 0.99
An N-terminal nuclear export signal regulates trafficking and aggregation of Huntingtin (Htt) protein exon 1. J Biol Chem (2013) 0.99
ROCK and PRK-2 mediate the inhibitory effect of Y-27632 on polyglutamine aggregation. FEBS Lett (2008) 0.98
Dynein mutations associated with hereditary motor neuropathies impair mitochondrial morphology and function with age. Neurobiol Dis (2013) 0.96
Acute and bilateral blindness due to optic neuropathy associated with copper deficiency. Arch Neurol (2009) 0.96
Clinical neurogenetics: amyotrophic lateral sclerosis. Neurol Clin (2013) 0.96
mTOR dysfunction contributes to vacuolar pathology and weakness in valosin-containing protein associated inclusion body myopathy. Hum Mol Genet (2012) 0.96
A knock-in mouse model for the R120G mutation of αB-crystallin recapitulates human hereditary myopathy and cataracts. PLoS One (2011) 0.95
Huntington disease and the huntingtin protein. Prog Mol Biol Transl Sci (2012) 0.95
The NIMA-family kinase Nek3 regulates microtubule acetylation in neurons. J Cell Sci (2009) 0.94
Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening. Proc Natl Acad Sci U S A (2009) 0.93
A common motif targets huntingtin and the androgen receptor to the proteasome. J Biol Chem (2008) 0.92
Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate. J Neurochem (2002) 0.91
F-actin binding regions on the androgen receptor and huntingtin increase aggregation and alter aggregate characteristics. PLoS One (2010) 0.90
Myopathy-causing mutations in an HSP40 chaperone disrupt processing of specific client conformers. J Biol Chem (2014) 0.90
AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization. ACS Chem Biol (2009) 0.90
Normal role of the low-molecular-weight neurofilament protein in mitochondrial dynamics and disruption in Charcot-Marie-Tooth disease. FASEB J (2011) 0.90
Design and implementation of cell-based assays to model human disease. ACS Chem Biol (2007) 0.89
High affinity binding of Hsp90 is triggered by multiple discrete segments of its kinase clients. Biochemistry (2003) 0.89
Prion-like propagation of protein aggregation and related therapeutic strategies. Neurotherapeutics (2013) 0.88
p62 expression and autophagy in αB-crystallin R120G mutant knock-in mouse model of hereditary cataract. Exp Eye Res (2013) 0.87
Mitochondrial pathology in immune and inflammatory myopathies. Curr Opin Rheumatol (2010) 0.87
Rapamycin-induced autophagy aggravates pathology and weakness in a mouse model of VCP-associated myopathy. Autophagy (2013) 0.87
A mechanism for death receptor discrimination by death adaptors. J Biol Chem (2005) 0.87
The expanding realm of prion phenomena in neurodegenerative disease. Prion (2009) 0.86
Intravitreal administration of HA-1077, a ROCK inhibitor, improves retinal function in a mouse model of huntington disease. PLoS One (2013) 0.86
Increased autophagy accelerates colchicine-induced muscle toxicity. Autophagy (2013) 0.85
Novel GNE mutations in two phenotypically distinct HIBM2 patients. Neuromuscul Disord (2010) 0.85
Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac function. FASEB J (2014) 0.84
An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors. Hum Mol Genet (2011) 0.84
Familial ALS with extreme phenotypic variability due to the I113T SOD1 mutation. Amyotroph Lateral Scler (2010) 0.84
In vivo kinetic approach reveals slow SOD1 turnover in the CNS. J Clin Invest (2015) 0.81
A dominant mutation in FBXO38 causes distal spinal muscular atrophy with calf predominance. Am J Hum Genet (2013) 0.81
Amyotrophic lateral sclerosis and organ donation: is there risk of disease transmission? Ann Neurol (2012) 0.79